Monday, October 26, 2009

Lethal Infection at Biogen Idec

Expect European regulators to likely recommend that the use of Biogen Idec’s (BIIB-$44.16) drug for relapsing forms of multiple sclerosis, Tysabri, include mandatory drug holidays after a determined length of use, as 23 cases of progressive multifocal leukoencephalopathy (PML) have been reported in those on therapy. How would this development impact recent sales momentum of Tysabri – e.g. for the first time since early 2008 Copaxone (glatiramer acetate) patients became the primary source of switches – and the growing importance of the MS drug to operating profitability?

Read more at BNET Pharma Industries….
Web Buzz: Biogen Idec Update – could there be a link between the seemingly higher prevalence of Tysabri-related PML cases in Germany and lack of oversight? Read More at BNET Pharma….

Editor David J Phillips does not hold a financial interest in any stocks mentioned n this article. The 10Q Detective has a Full Disclosure Policy.

No comments: